Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02965716
Title Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

melanoma

Therapies

Pembrolizumab + Talimogene laherparepvec

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.